Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with a terminal chronic liver disease have a disordered bone metabolism resulting in
a higher risk of falling ill with osteoporosis. Although liver transplantation restores liver
function, immunosuppressive therapy (especially corticosteroids) after transplantation
increases again the risk of osteoporosis and bone fragility. Zoledronate, a bisphosphonate,
slows down the destruction of bone. The purpose of this study is to determine whether
bisphosphonates are effective in the prevention of osteoporosis following immunosuppressive
therapy after liver transplantation.